Table 2.
Baseline clinical and lung function characteristics, change of lung function, and progression in patients.
| Expose (n = 59) | Simple silicosis (n = 129) | Complicated silicosis (n = 149) | p | |
|---|---|---|---|---|
| Initial dyspnea MRC ≥ 2; n (%) | 16 (27.1%) | 78 (60.5%) | 118 (79.2%) | < 0.001 |
| Initial 6-min test (meters); average (SD) | 445.0 (73.8) | 415.0 (100.9) | 390.0 (84.9) | 0.021 |
| Initial FVC/FEV1 ratio; average (SD) | 79.4 (8.3) | 76.9 (9.2) | 67.8 (13.1) | < 0.001 |
| Initial TLC (expected%); average (SD) | 90.6 (12.3) | 86.5 (13.3) | 77.1 (15.5) | < 0.001 |
| Initial DLCO (expected%); average (SD) | 88.5 (19.9) | 85.5 (16.4) | 70.5 (19.6) | < 0.001 |
| FVC/FEV < 70 in follow-up; n (%) | 8 (14.3%) | 22 (17.3%) | 73 (49.0%) | < 0.001 |
| FVC > 10% decrease in follow-up; n (%) | 8 (24.2%) | 17 (15.2%) | 40 (30.3%) | 0.021 |
| DLCO decrease in follow-up; n (%) | 2 (9.1%) | 19 (20.0%) | 43 (36.8%) | 0.003 |
| Progression; n (%) | 0 (0.0%) | 39 (30.2%) | 94 (63.1%) | < 0.001 |
| Death; n (%) | 4 (6.8%) | 13 (10.2%) | 48 (32.2%) | < 0.001 |
Statistical significance was determined using χ2 test and ANOVA test for qualitative and continuous variables, respectively.
*p < 0.05; **p < 0.001.